HTB homepage • Conference reports • Articles by subject • Subscribe 14 July 2005 Contents Conference reports Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure Predicting clinical responses to ddI from genotypic resistance Under-detection of transmission of transmitted resistance and impact on treatment response Risk of death in UK after diagnosis of 3-class resistance Antiretrovirals TMC-114 to be submitted for registration based on Phase 2b trial results: expanded access expected in UK in Autumn 2005 Tipranavir (Aptivus) approved in US FDA fast track designation for CCR5 inhibitor vicriviroc (SCH-D) Pfizer discontinues development of capravirine Treatment access Six Indian generic ARVs are given FDA tentative approval Methadone and buprenorphine added to WHO list of essential medicines MSF’s pricing guide to purchasing ARVs: 8th edition online WHO 3 by 5 progress report Pregnancy Use of T-20 in pregnancy: case study shows transmission occurred in highly treatment experienced mother with multiple-drug resistance Further reading on nevirapine resistance Vaccines and microbicides Human Papilloma Virus vaccines a review of advances in the development of HPV vaccines Other news CDC estimate over 1 million HIV-positive people in US Newly diagnosed HIV infection – review in UK and Ireland Re-emergence of syphilis in the UK: the new epidemic phases Prescription of heroin is less costly for society On the web Medscape full text articles HIV inSite Knowledge Base HTB homepage • Conference reports • Articles by subject • Subscribe
